Direct thrombin inhibitors built on the azaphenylalanine scaffold provoke degranulation of mast cells

Summary

The main structural feature of direct thrombin inhibitor LK-732 responsible for the appropriate interaction at the thrombin active site is a strong basic group. A possibility that a strong basic group of LK-732 might contribute to the mast cell degranulation effect and consequent reduction of tracheal air flow (TAF) and fall of mean arterial blood pressure (MAP) in rats was investigated in the present study. At doses up to5 mg/kg (i. v.), LK-732 did not cause significant changes of TAF and MAP. At 7 mg/kg (i. v.),a sudden reduction of TAF and a fall of MAP was observed within 5 min after LK-732 administration (75% mortality, p=0. 007). A less basic direct thrombin inhibitor LK-658 (21 mg/ kg, i. v.) did not significantly disturb TAF and MAP. A reduction of TAF and a fall of MAP caused by LK-732 (7 mg/kg, i. v.) was almost completely abolished in rats with degranulated mast cells (0% mortality, p=0. 008). LK-732 concentration-dependently degranulated rat peritoneal mast cells in vitro (pEC₅₀=1. 92±0. 05 µM). A structure-activity relationship (SAR) study revealed that the terminal basic groups attached to the aromatic ring are responsible for the mast cell degranulation effect. A good correlation was observed between mast cell degranulation and pK_b of analogues of LK-732 (R²=0. 49), but not between mast cell degranulation and thrombin K_i (R²=0. 23). LK-732-induced reduction of TAF, the fall of MAP and high mortality originate from LK732-induced mast cell degranulation. As judged by the SAR study, this effect could be overcome by reducing the basicity of LK-732.

Keywords

Thrombin inhibitors - azaphenylalanine scaffold - mast cell degranulation - basicity - rat

• References

• 1 Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005; 04: 410-20.
• 2 Levine MN, Raskob G, Beyth RJ. et al. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 Suppl 287-310.
• 3 Obreza A, Stegnar M, Trampuš-Bakija A. et al. Synthesis and in vitro evaluation of new azaphenylalanine derivatives as serine protease inhibitors. Pharmazie 2004; 59: 739-43.
• 4 Zega A, Mlinšek G, Šolmajer T. et al. Thrombin inhibitors built on an azaphenylalanine scaffold. Bioorg Med Chem Lett 2004; 14: 1563-67.
• 5 Peternel L, Stegnar M, Drevenšek G. et al. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. Thromb Haemost 2005; 93: 437-42.
• 6 Hauptmann J, Markwardt F. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Semin Thromb Hemost 1992; 18: 200-17.
• 7 Kaiser B, Hauptmann J, Weiss A. et al. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed Biochim Acta 1985; 44: 1201-10.
• 8 Metcalfe DD. Effector cell heterogeneity in immediate hypersensitivity reactions. Clin Rev Allergy 1983; 01: 311-25.
• 9 Schwartz LB. Mast cells and basophils. Clin Allergy Immunol 2002; 16: 3-42.
• 10 Paton WD. Histamine release by compounds of simple chemical structure. Pharmacol Rev 1957; 09: 269-328.
• 11 Lagunoff D, Martin TW. Agents that release histamine from mast cells. Ann Rev Pharmacol Toxicol 1983; 23: 331-51.
• 12 Pearce FL. Non-IgE-mediated mast cell stimulation. Ciba Found Symp 1989; 147: 74-87.
• 13 Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77: 1033-79.
• 14 Mousli M, Hugli TE, Landry Y. et al. Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology 1994; 27: 1-11.
• 15 Tharp MD, Kagey-Sobotka A, Fox CC. et al. Functional heterogeneity of human mast cells from different anatomic sites: in vitro responses to morphine sulfate. J Allergy Clin Immunol 1987; 79: 646-53.
• 16 Theoharides TC, Askenase P. Autacoids. In: Essentials of pharmacology. Little, Brown and Company; 1996: 187-215.
• 17 Mori K, Maru C, Takasuna K. Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro. J Pharm Pharmacol 2000; 52: 577-84.
• 18 Macia RA, Silver AC, Gabel RA. et al. Hypotension induced by vasopressin antagonists in rats: role of mast cell degranulation. Toxicol Appl Pharmacol 1990; 102: 117-27.
• 19 Murphy DJ, Joran ME. Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat. Fundam Appl Toxicol 1992; 18: 307-13.
• 20 Moss J. Muscle relaxants and histamine release. Acta Anaesthesiol Scand Suppl 1995; 106: 7-12.
• 21 Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci 1993; 53: 1391-9.
• 22 Markowitz S, Saito K, Buzzi MG. et al. The development of neurogenic plasma extravasation in the rat dura mater does not depend upon the degranulation of mast cells. Brain Res 1989; 477: 157-65.
• 23 Knudsen T, Ferjan I, Johansen T. Effect of oubain, digoxin and digitoxigenin on potassium uptake and histamine release from rat peritoneal mast cells. FEBS Lett 1993; 321: 127-31.
• 24 Nosal R, Slorach SA, Uvnas B. Quantitative correlation between degranulation and histamine release following exposure of rat mast cells to compound 48/80 in vitro. Acta Physiol Scand 1970; 80: 215-21.
• 25 Shore PA, Burkhalter A, Cohn VH. A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther 1959; 127: 182-6.
• 26 Macia RA, Gabel RA, Reginato MJ. et al. Hypotension induced by growth-hormone-releasing peptide is mediated by mast cell serotonin release in the rat. Toxicol Appl Pharmacol 1990; 104: 403-10.
• 27 Ferry X, Brehin S, Kamel R. et al. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 2002; 23: 1507-15.
• 28 Mori K, Shibano M, Satoh H. et al. Differential response of mast cells separated from various organs and basophils of dogs to the fluoroquinolone antimicrobial levofloxacin. Arch Toxicol 2001; 75: 227-33.
• 29 Ishizaka T, Dvorak AM, Conrad DH. et al. Morphologic and immunologic characterization of human basophils developed in cultures of cord blood mononuclear cells. J Immunol 1985; 134: 532-40.
• 30 Ebertz JM, Hermens JM, McMillan JC. et al. Functional differences between human cutaneous mast cells and basophils: a comparison of morphine-induced histamine release. Agents Actions 1986; 18: 455-62.
• 31 Stellato C, de Paulis A, Cirillo R. et al. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991; 74: 1078-86.
• 32 Williams PD, Laska DA, Shetler TJ. et al. Vancomycin-induced release of histamine from rat peritoneal mast cells and a rat basophil cell line (RBL-1). Agents Actions 1991; 32: 217-23.
• 33 Mousli M, Bronner C, Landry Y. et al. Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett 1990; 59: 260-2.
• 34 Bala S, Weaver J, Hastings KL. Clinical relevance of preclinical testing for allergic side effects. Toxicology 2005; 209: 195-200.
• 35 Lawrence ID, Warner JA, Cohan VL. et al. Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J Immunol 1987; 139: 3062-9.
• 36 Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant / antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002; 57: 751-8.